Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

myeloproliferative neoplasms (MPN), and chronic or accelerated phase MPN-unclassifiable (MPN-U) and MDS-MPN. Blast crisis phase of MPNs are considered secondary AML and will be included in the AML cohort.

  • 0 views
  • 31 Jan, 2021
  • 3 locations
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.

decitabine
sgi-110
bone marrow procedure
myeloproliferative disorder
azacitidine
  • 17 views
  • 25 Jan, 2021
  • 5 locations
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

. 4. Myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic myelomonocytic leukemia [myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS

chronic myelomonocytic leukemia
leukemia
myelodysplastic syndromes
myelomonocytic leukemia
bone marrow transplant
  • 10 views
  • 07 Nov, 2020
  • 14 locations
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given

aspirin
blast crisis
polycythemia vera
anagrelide
leukemia
  • 12 views
  • 26 Jan, 2021
  • 1 location
Salsalate Venetoclax and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of

TP53
induction therapy
leukemia
myeloid leukemia
secondary aml
  • 0 views
  • 26 Jan, 2021
  • 1 location
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping

procrit
TP53
filgrastim
colony stimulating factor
leukemia
  • 0 views
  • 25 Jan, 2021
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts.

  • 0 views
  • 29 Jan, 2021
  • 6 locations
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome. PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used …

blast cells
hemolysis
colony stimulating factor
leukemia
myeloid leukemia
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Haploidentical Hematopoietic Cell Transplantation

Neoplasms (MPN.

cell transplantation
blast cells
cyclophosphamide
graft versus host disease
myeloid leukemia
  • 4 views
  • 27 Jan, 2021
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

side effects are seen in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML), or Myelofibrosis (MF

blast cells
myelodysplastic/myeloproliferative neoplasms
hemolysis
graft versus host disease
leukemia
  • 50 views
  • 25 Jan, 2021